The Promise of Low Dose Naltrexone Therapy

Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders

Nonfiction, Health & Well Being, Health
Cover of the book The Promise of Low Dose Naltrexone Therapy by Elaine A. Moore, Samantha Wilkinson, McFarland & Company, Inc., Publishers
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Elaine A. Moore, Samantha Wilkinson ISBN: 9780786452583
Publisher: McFarland & Company, Inc., Publishers Publication: January 22, 2009
Imprint: Language: English
Author: Elaine A. Moore, Samantha Wilkinson
ISBN: 9780786452583
Publisher: McFarland & Company, Inc., Publishers
Publication: January 22, 2009
Imprint:
Language: English

Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn’s disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn’s disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers.

More books from McFarland & Company, Inc., Publishers

Cover of the book Mission Ukraine by Elaine A. Moore, Samantha Wilkinson
Cover of the book The Radio Boys and Girls by Elaine A. Moore, Samantha Wilkinson
Cover of the book Wars of Latin America, 1948-1982 by Elaine A. Moore, Samantha Wilkinson
Cover of the book Scapegoat of Shiloh by Elaine A. Moore, Samantha Wilkinson
Cover of the book The Ripper's Victims in Print by Elaine A. Moore, Samantha Wilkinson
Cover of the book Documenting the Black Experience by Elaine A. Moore, Samantha Wilkinson
Cover of the book Gothic in Comics and Graphic Novels by Elaine A. Moore, Samantha Wilkinson
Cover of the book The Pennsylvania Reserves in the Civil War by Elaine A. Moore, Samantha Wilkinson
Cover of the book Of Tribes and Tribulations by Elaine A. Moore, Samantha Wilkinson
Cover of the book The Weaponizing of Biology by Elaine A. Moore, Samantha Wilkinson
Cover of the book Henry Frye by Elaine A. Moore, Samantha Wilkinson
Cover of the book Hitchcock and Humor by Elaine A. Moore, Samantha Wilkinson
Cover of the book Immigration and America's Cities by Elaine A. Moore, Samantha Wilkinson
Cover of the book Women Writers of Yiddish Literature by Elaine A. Moore, Samantha Wilkinson
Cover of the book Coming Back to a Theater Near You by Elaine A. Moore, Samantha Wilkinson
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy